Preductal

Quick links to important sections

Preductal

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Preductal

Property Description
Active ingredient Trimetazidine dihydrochloride
Form Film-coated or Modified-release (MR) tablets
Pharmacological class Anti-ischemic metabolic agent
General purpose Enhances the metabolic efficiency of heart cells
Origin Synthetic (Piperazine derivative)

What is Trimetazidine? Defining the Drug's Identity

The medicinal entity Preductal is the trade name for the drug containing the active substance Trimetazidine, chemically known as Trimetazidine dihydrochloride. This compound is classified as an anti-ischemic metabolic agent, representing a unique pharmacological approach to cardiovascular support. Trimetazidine is a synthetic compound derived from the piperazine chemical structure. This positioning as a metabolic agent ensures its action focuses on internal cellular efficiency, a mechanism recognized for its benefits in supporting myocardial function.

Composition and Pharmaceutical Forms

The core composition of Preductal relies exclusively on the Trimetazidine dihydrochloride active ingredient, which is formulated for the oral route of administration and is available as a prescription-only medication. The medicine is typically available as a film-coated tablet and, commonly, as a modified-release tablet (MR). This modified-release form is specifically engineered to ensure the continuous and sustained release of the active substance over a longer period. This controlled delivery mechanism facilitates the consistent optimization of the heart cell's energy state throughout the day.

General Therapeutic Purpose and Action

The general purpose of Trimetazidine is to function as a cytoprotective agent that enhances the heart muscle's tolerance to periods of insufficient oxygen supply, a state known as ischemia. It achieves this by acting as a metabolic modulator within the cardiac cells. Trimetazidine helps optimize energy utilization in the myocardium during ischemia. The drug supports the heart by ensuring its cells can function better even when their oxygen supply is restricted, particularly in a typical use scenario for improving cardiac resilience. This protective, non-hemodynamic mechanism serves as foundational support for heart function in such conditions.

Regulatory References

  1. EMA Trimetazidine Referral Overview

What side effects are possible with Preductal?

Possible Side Effects and Safety Information

The safety profile of Trimetazidine is structured by regulatory authorities based on the frequency of observed adverse reactions and the specific System-Organ Class affected. The following summarizes official safety information without providing clinical instructions.

Classification of Adverse Reactions

Adverse reactions are formally categorized by their reported frequency:

  • Common Reactions (may affect up to 1 in 10 people): Reactions frequently documented in regulatory labels involve the Nervous System (dizziness, headache) and Gastrointestinal System (abdominal pain, nausea, vomiting, diarrhoea, dyspepsia). Skin and Subcutaneous Tissue reactions like rash and pruritus are also common.

  • Rare Reactions (may affect up to 1 in 1,000 people): These include effects on the Cardiovascular System, specifically palpitations, tachycardia (rapid heart rate), and arterial hypotension (low blood pressure).

  • Frequency Not Known: This category includes reports from post-marketing surveillance, such as symptoms of Parkinsonism (tremor, gait instability), hepatitis, and severe blood disorders like agranulocytosis and thrombocytopenia.

Safety Restrictions and Serious Reactions

The medicine is officially contraindicated in patients with pre-existing Parkinson's disease or related movement disorders, which are classified as serious adverse reactions. Official documentation also restricts use in individuals with severe renal impairment (significant kidney function problems).

It is officially noted that dizziness and low blood pressure upon standing (orthostatic hypotension) may be observed when treatment is initiated. Furthermore, any documented Parkinsonian symptoms are generally observed to be reversible upon permanent discontinuation of Trimetazidine.

Overdose and Emergency Response

Documented Overdose Manifestations and Risks

Official regulatory documentation notes that cases of massive overdosage have been primarily associated with cardiovascular effects. The documented clinical manifestation is severe hypotension, or significantly low blood pressure. This severe drop in blood pressure represents the main life-threatening outcome identified in the context of acute overdosage, requiring urgent stabilization.

Required Emergency Actions

Regulatory guidance requires immediate action in all instances of suspected overdosage. Authorities mandate that users seek emergency medical attention or consult a doctor or pharmacist immediately if an excess amount of the drug has been taken. This instruction is based on the potential for severe, documented physiological effects and the need for immediate supportive management.

Official Treatment Protocol

There is no specific treatment or antidote available for Trimetazidine overdosage listed in the official prescribing information. Consequently, the mandated management protocol is focused entirely on supportive care. Treatment must be symptomatic, with necessary supportive measures instituted by medical professionals to manage vital signs, particularly blood pressure, until the drug is naturally eliminated from the body.

Therapeutic Uses of Preductal

What Preductal Treats: Main Uses and Benefits

Trimetazidine is commonly used in adults as an add-on therapy for the symptomatic management of stable angina pectoris, a core condition within chronic coronary syndrome. It is applied when patients are inadequately controlled by or intolerant to first-line anti-anginal therapies.

The medicine is relevant for managing symptoms linked to organ-specific functional stress and symptoms that create noticeable physiological strain. It is commonly used to help manage symptoms of stable angina, exertion-induced chest pain, and reduced exercise tolerance.

“The therapy may assist with symptomatic relief during difficult episodes and supports the patient in maintaining a sense of stability for routine activities.”

Improving Functional Capacity

The medication may assist with managing symptomatic patterns that interfere with daily functioning, and is considered relevant for supporting exercise tolerance. This benefit is commonly used in clinical settings where symptoms create noticeable physiological strain during physical exertion. This supports patients by aiming to assist with maintaining functional stability for routine activities. The overall symptomatic support provided may help ease the symptom burden, which can contribute to a decreased reliance on short-acting nitrate medications for immediate relief during episodes of discomfort.


Quick Fact: Relief for Angina Discomfort
Trimetazidine is applied in contexts involving recurrent or episodic manifestations of stable angina and is commonly used to help with the frequency and intensity of these attacks.

Regulatory References

  1. European Medicines Agency

Eligibility and Restrictions for Use

Who Can and Cannot Use Preductal? (Trimetazidine)

Official regulatory documents define strict population eligibility rules for the use of Trimetazidine (Preductal).

Contraindications and Prohibited Populations

Use of this medicine is absolutely prohibited (contraindicated) for several specific groups:

  • Patients with known hypersensitivity to the active substance or any excipient.
  • Patients diagnosed with Parkinson disease or who exhibit Parkinsonian symptoms (e.g., tremor, hypertonia, unbalanced walk), restless leg syndrome, and other related movement disorders.
  • Patients with severe renal impairment, defined as a Creatinine Clearance (CrCl) less than 30 mL/min.

Eligibility Based on Age and Physiological Status

Population Group Eligibility Status Regulatory Basis
Adults Allowed Indicated only for the adult population for stable angina.
Pediatric (under 18) Not Recommended Safety and efficacy have not been established.
Elderly (over 75) Caution Required Advised due to potential age-related decrease in renal function.
Pregnancy Avoided Use is preferably avoided due to lack of adequate human data.
Breastfeeding Not Recommended Based on the absence of data regarding excretion into breast milk.

Condition-Specific Restrictions

Patients with moderate renal impairment (CrCl 30-60 mL/min) are not contraindicated but are subject to a conditional use restriction and require caution, as documented in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding Trimetazidine (Preductal) interactions is primarily defined by the absence of documented findings.

Interaction Scope Official Regulatory Statement
Interacting medicinal products or categories None formally identified or reported in regulatory studies.
Mechanistic basis of interactions None documented; the prescribing information explicitly states that no drug interactions have been identified.
Timing-based interaction rules No mandatory time separation is required from other medicinal products based on interaction risk.
Food, alcohol, or substance interactions No interactions with foodstuffs have been found. The drug's characteristics are officially documented as not influenced by meals.

Population-Specific Pharmacokinetic Considerations

While specific drug-drug interactions are not documented, official labeling does highlight constraints related to the drug’s elimination (clearance):

  • Expected increased exposure is noted for patients who are elderly (over 75 years old) and individuals with moderate renal impairment (creatinine clearance 30-60 ml/min). This is due to the age-related and condition-related decrease in renal clearance.
  • Contraindication: The medicine is contraindicated in patients with severe renal impairment (creatinine clearance < 30 ml/min) because of the significant risk of excessive drug accumulation and increased systemic exposure.

The overall official interaction profile is characterized by a reliance on clearance-related patient status rather than interactions with co-administered medicinal products.

Mechanism of Action

How Preductal Works: Mechanism of Action

Energy Efficiency via Metabolic Shift

This core mechanism involves the drug acting as a selective metabolic inhibitor within the heart cell’s mitochondria, primarily by partially blocking the enzyme 3-ketoacyl-CoA thiolase (3-KAT).

This inhibition redirects the cell's energy source away from fatty acid oxidation toward glucose oxidation, which is a more oxygen-efficient pathway for ATP generation. The metabolic shift contributes to the preservation of high-energy phosphate stores ( ATP) within the cell.

Preserving Cellular Function Under Stress

The resulting metabolic switch enhances the heart muscle's oxygen utilization efficiency, yielding a higher ratio of ATP molecules generated per unit of oxygen consumed. This key physiological effect facilitates the stabilization of the cell's internal environment, preserving ionic balance and structural integrity. The mechanism provides a basis for the myocardium to maintain its cellular integrity and function under conditions where oxygen supply might be limited.

Dosage and Administration Information

Official Administration Guidelines

Trimetazidine is administered exclusively by the oral route as a prescription-only medication. The official instructions for its use are defined by its pharmacological form and specific patient factors.


Instruction Detail
Standard Dosing One 35 mg Modified-Release (MR) tablet, taken twice daily (B.I.D.).
Timing in Relation to Meals The tablet must be taken during meals (specifically noted as the morning and evening meals).
Preparation The MR tablet must be swallowed whole with water. It is prohibited to chew, crush, or break the tablet to maintain its prolonged-release characteristics.
Missed Dose If a dose is missed, the patient should take the next dose at the usual time and must not take a double dose to compensate.
Treatment Duration The benefit of the treatment should be formally assessed after three months. If no response is observed, the treatment should be discontinued.

Special Procedural Conditions

Dosage adjustments are specifically mandated for certain patient groups. For patients with moderate renal impairment (creatinine clearance 30–60 mL/min), the dose is reduced to one 35 mg MR tablet once daily with the morning meal. This medicine is not recommended for children under 18 years, and older adults (over 75 years) with moderate renal impairment should also follow the reduced once-daily regimen. The drug is for maintenance therapy and is not indicated for the initial treatment of unstable angina or for use during an acute angina attack.

These instructions collectively establish a clear, structured protocol for the safe and consistent oral administration of Trimetazidine under non-acute conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes published research and clinical trials that have evaluated the compound. It is important to remember that individual results may vary, and this information should not be interpreted as medical advice.

Focus of Research

Research examined this formulation against older generations of the compound.

Evidence Profile in Clinical Studies

A range of studies, including randomized controlled trials (RCTs) and observational research, have investigated the compound's potential applications.

Studies on Pain and Inflammation

  • Acute Back Pain: A study investigated the impact on acute back pain symptoms. Some trials investigated the compound's effect on migraine frequency. Research also examined the role of the compound in relation to inflammation and immune response modulation.
  • Chronic Fatigue Syndrome (CFS): Clinical trials investigated the compound in relation to chronic fatigue symptoms. Findings from smaller trials were mixed, and current evidence remains limited regarding long-term outcomes.

Studies on Respiratory Health

  • Common Cold: Research examined the compound in relation to the duration and severity of common colds. This area requires larger, independent studies for further clarification.

Studies on Cognitive Function

  • Age-Related Decline: Research explored whether the combination affected cognitive function in adults over 65. Initial studies examined the use of a low dose to evaluate potential outcomes. The long-term impact on overall mental health is not yet clear.

Important Considerations

Information presented here is for research awareness only.

Frequently Asked Questions (FAQ)

Common questions about Preductal (FAQ)

Q: How is the mechanism of Preductal different from traditional angina medications?

According to official documents, Preductal (Trimetazidine) is categorized as a metabolic agent. Its core function is to enhance the heart muscle cell's ability to use oxygen-efficient fuel, such as glucose. This approach contrasts with traditional angina medications that primarily work by changing blood vessel dynamics. Regulatory information indicates it is used as an add-on therapy when initial treatments are not fully effective or cannot be tolerated.


Q: How long does it typically take to notice the full benefits of Preductal treatment?

Clinical research, cited in regulatory reviews, indicates that a beneficial effect on exercise tolerance and angina symptoms often becomes evident within approximately two to three months after starting treatment. Official guidelines stipulate that the benefit of the treatment must be formally assessed by a healthcare professional after three months to determine its effectiveness.


Q: What is the official information regarding interactions between Preductal and Metoclopramide?

Official regulatory information specifies that no drug-drug interactions have been formally identified for Preductal, including with co-administered medicinal products. This statement relies on controlled studies and safety reports submitted to regulatory agencies.


Q: Is long-term use of Preductal considered safe for patients with stable angina?

Regulatory documents state that the benefit of the treatment is subject to a formal assessment after three months. If a therapeutic response is observed during this review, official information describes that the medicine is eligible for continuation as a maintenance therapy under ongoing medical supervision.


Q: What are the symptoms of a potential allergic reaction to Preductal?

Signs of a serious allergic reaction, as described in official patient information, may include a severe generalized red skin rash with blistering. Other signs are swelling of the face, lips, tongue, or throat, which can cause difficulty in swallowing or breathing.


Q: Does Preductal have any effect on a person's blood sugar levels?

Due to its mechanism of action, which involves shifting cellular metabolism toward glucose oxidation (using glucose for energy), studies have shown that it can be associated with an improvement in glucose metabolism in certain patients.


Q: Are there specific symptoms that require immediate medical attention while on Preductal?

Official product information states that it is necessary to seek medical attention without delay if specific serious symptoms are observed. These symptoms include signs of a severe allergic reaction (such as swelling or breathing difficulty) or symptoms that suggest an overdose.


Q: Is Preductal a treatment for high blood pressure?

Regulatory documents list the medicine's primary use for stable angina pectoris; it is not indicated as a treatment for high blood pressure. Low blood pressure, or arterial hypotension, is listed as a rare side effect in the official safety profile.


Q: Can Preductal be used to help with symptoms of vertigo or tinnitus?

Regulatory agencies have concluded through reviews that the benefits of the medicine no longer outweigh the risks for treating symptoms of vertigo, tinnitus, and visual disturbances. These uses have been formally withdrawn from official authorization.


Q: Can Preductal affect one's ability to drive or operate machinery?

Due to the potential for common side effects such as dizziness and drowsiness, official documentation indicates that caution should be exercised regarding driving or using complex machinery.


Q: What information is available about Preductal's use in patients with liver problems?

Official regulatory documentation specifies that no dosage adjustments are typically required for patients who have impaired hepatic (liver) function.


Q: Is Preductal always used as an 'add-on' therapy to existing treatments?

The medicine is officially indicated for stable angina pectoris as add-on therapy. This means it is used for patients whose condition is inadequately controlled by, or who are intolerant to, their first-line treatments.


Q: Is there any official information about Preductal and its status on the World Anti-Doping Agency list?

Trimetazidine is listed by the World Anti-Doping Agency (WADA) as a prohibited substance. It is categorized under Hormone and Metabolic Modulators on the official list.


Q: Can Preductal cause changes in mood or lead to depression?

Official drug information lists depression as an adverse effect that has been reported during use. The frequency of this side effect is currently described as unknown in regulatory documents.

How should Preductal be stored and disposed of?

How to Store and Dispose of Preductal?

Regulatory labeling specifies strict conditions for the storage and disposal of trimetazidine (Preductal) to maintain product stability and ensure public safety.


Official Storage Requirements

Storage Component Requirement
Temperature Limit Store the product at a temperature not exceeding 30 C (86 F).
Child Safety Must be kept out of the sight and reach of children.
Protection Requires protection from excessive heat to maintain stability.

Official Disposal Rules

Unused or expired trimetazidine must be managed according to pharmaceutical waste protocols. Regulatory instructions mandate that the medicine must not be disposed of via wastewater or household waste. All disposal must be carried out in accordance with local requirements, typically by returning the product to a pharmacist or official collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Preductal found in:

A-Z Index: